Combined Early Steroid Response and MRD Improve Risk Stratification in Pediatric Acute Lymphoblastic Leukemia: The CCCG ‐ ALL ‐2015 Study
- 18 May 2026
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 117 (4) , 966-972
Abstract
Objective: To determine whether early dexamethasone response provides complementary prognostic information to minimal residual disease (MRD) and whether integrating both markers refines risk stratification in pediatric acute lymphoblastic leukemia (ALL). Methods: We retrospectively analyzed pediatric ALL patients treated at a single center according to the CCCG‐ALL‐2015 protocol. Day 5 steroid response was classified as dexamethasone good response (DGR) or dexamethasone poor response (DPR). Bone marrow MRD was measured on Days 19 and 46 of induction. A four‐quadrant classification was constructed by combining Day 5 steroid response with Day 46 MRD status (DGR/MRD−, DGR/MRD+, DPR/MRD−, DPR/MRD+) to evaluate event‐free survival (EFS) and cumulative incidence of relapse (CIR). Results: Among 312 patients, 220 were DGR and 92 were DPR. MRD negativity rates on Days 19 and 46 were significantly lower in DPR. Among 304 patients with paired MRD measurements, 181, 102, 18, and 3 patients were classified as D19−/D46−, D19+/D46−, D19+/D46+, and D19−/D46+, respectively, with progressively worse 5‐year EFS and increasing 5‐year CIR. In the four‐quadrant analysis, EFS differed significantly across groups, and compared with DGR/MRD−, the other quadrants exhibited higher event risk. In multivariable Cox models, Day 46 MRD remained independently associated with inferior EFS (HR = 2.429, 95% CI: 1.286–4.590; p = 0.006). When the four‐quadrant classification was entered into the multivariable model (reference: DGR/MRD−), DGR/MRD+ (HR = 4.319, 95% CI 1.792–10.414; p = 0.001), DPR/MRD− (HR = 2.207, 95% CI: 1.253–3.888; p = 0.006), and DPR/MRD+ (HR = 3.718, 95% CI: 1.608–8.598; p = 0.002) were each associated with increased event risk. Conclusions: MRD kinetics identify patients with delayed clearance or persistent positivity at higher relapse risk. Integrating early steroid response with MRD using a four‐quadrant framework may complement MRD‐based assessment and further refine risk stratification by highlighting clinically meaningful discordant subgroups.Keywords
Funding Information
- National Key Research and Development Program of China (2023YFC2706301)
This publication has 15 references indexed in Scilit:
- Acute lymphoblastic leukemia relapse: biomarkers, hopes, and challengesTrends in Molecular Medicine, 2025
- Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALLBlood, 2025
- Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL)Current Treatment Options in Oncology, 2024
- Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG‐ALL‐2015: A multicenter studyCancer, 2023
- Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment responseNature Medicine, 2023
- Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed TherapyBlood Cancer Discovery, 2021
- Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiationBlood, 2021
- To delay or not to delay, that is the question for patients with acute lymphoblastic leukemia who do not receive prophylactic cranial irradiationCancer, 2018
- Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapyLeukemia, 2016
- Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective studyThe Lancet Oncology, 2015